ライフサイエンスコーパス: YFV

1 YFV induced a robust NK cell response in vivo, with an e

2 YFV induced an increased functional responsiveness to IL

3 YFV infection in mice resulted in impaired TCR signaling

4 YFV infection of macaques and hFRG mice caused substanti

5 YFV vaccination administered through either route was we

6 YFV vaccination of patients with AD through the transcut

7 YFV/dengue-4 virus, but not YFV/dengue-2 virus, was neur

8 The live attenuated 17D YFV strain induces responses characterized by neutralizi

9 smitted flaviviruses yellow fever virus 17D (YFV) and dengue virus type 2 (DENV2).

10 cell response to the yellow fever virus 17D (YFV-17D) vaccine.

11 Genomic sequencing of 18 YFV genomes revealed the estimated timing, source, and l

12 ents with severe YFV infection, we tested 37 YFV-specific monoclonal antibodies isolated from vaccina

13 Here, based on studies using a YFV replicon-based trans-packaging system as well as ful

14 CD8(+) T cell responses, less is known about YFV-specific CD4(+) T cells.

15 The acute YFV-specific effector CD8 T cell response was broad and

16 Additionally, YFV-specific memory B cells were readily detectable at 2

17 the ER-resident cochaperone DNAJC14 affects YFV polyprotein processing at the NS3/4A site.

18 we show that DNAJC14 overexpression affects YFV polyprotein processing and alters RC assembly.

19 s macaques using a highly pathogenic African YFV strain.

20 primed by type I/III IFN in vivo early after YFV infection and that their response is governed primar

21 king the protective effect of IFN-a2 against YFV vaccine strains.

22 -PCR in five Callithrix monkeys who were all YFV-negative by histopathology or immunohistochemistry s

23 Epitopes were present within all YFV proteins, but the capsid, envelope, NS2a, and NS3 pr

24 he 3' NCRs of 117 isolates of South American YFV have been examined, and major deletions and/or dupli

25 omparable to those of typical South American YFV isolates, and mosquito infectivity trials demonstrat

26 XL isolates, as well as other South American YFV isolates, were evaluated for three phenotypes: growt

27 ique to and shared among most South American YFV strains.

28 this route, highlighting its potential among YFV transmission risks.

29 in vivo safety and antiviral efficacy of an YFV NS4B inhibitor in an animal model.

30 n by the high neurovirulence of an analogous YFV/JEV Nakayama chimera derived from the wild JEV Nakay

31 putative host factors required for DENV and YFV infection.

32 tion was overall less competent for DENV and YFV than an urban population of Aedes aegypti.

33 tively modest vector competence for DENV and YFV, combined with a lack of detectable attraction to hu

34 cific membrane targeting of both DNAJC14 and YFV replication proteins, the formation of protein inter

35 Expression of this vsRNA and YFV infection of T cells reduced the expression of a Src

36 supported sustained replication of ZIKV and YFV, but not DENV.

37 tested for both predispositions before anti-YFV vaccination.

38 not rescue the YFV NS5-STAT2 interaction, as YFV NS5 is also unable to interact with hSTAT2 in murine

39 es suggested a potential association between YFV viremia and mortality.

40 No relationship was found between YFV immunity and time in endemic countries, other flaviv

41 The differences in virion morphology between YFV strains also contribute to the reduced sensitivity o

42 Both YFV and ZKV replicated in human T cells in vitro; howeve

43 In Brazil, YFV is maintained by a sylvatic transmission cycle invol

44 e expression of flavivirus NS5 protein or by YFV infection, and mumps infection did not alter CD4 mRN

45 While several studies have characterized YFV-specific antibody and CD8(+) T cell responses, less

46 The chimera (YFV/JEV SA14-14-2, or ChimeriVax-JE) is less neurovirule

47 In Sao Paulo city, YFV was detected in October 2017 in Aloutta monkeys in a

48 asing the representation of dominant clones, YFV vaccination recruits rare and more responsive T cell

49 Hsp40 family protein is sufficient to confer YFV-inhibitory activity.

50 B) with serine, threonine or alanine confers YFV resistance to BDAA without apparent loss of replicat

51 Eighty-four patients with confirmed YFV infection were included.

52 As frequencies subsequently declined, YFV-specific cells regained CCR7 expression, indicating

53 This study demonstrates YFV transmission through breastfeeding in an animal mode

54 S5 proteins of ZIKV and dengue virus (DENV), YFV NS5 protein is able to bind hSTAT2 but not murine ST

55 alidated as essential host factors for DENV, YFV, and ZIKV infection in two human cell lines: A549 lu

56 We report that DENV, YFV and Zika virus (ZIKV) infections were strikingly inh

57 We detect (-) YFV-17D RNA in specific secondary lymphoid compartments

58 ion, even in participants without detectable YFV RNA.

59 Neutralization assays were used to determine YFV immunity.

60 The engineered YFV-17D systems can be used to express fluorescent marke

61 We showed that during the recent epidemic, YFV was reintroduced from Minas Gerais to the Espirito S

62 After vaccination, pre-existing YFV-specific T cell populations with low clonal diversit

63 of chicken B (RP9) lymphoma cells expressing YFV as an epitope-tagged transgene.

64 breaks of Chikungunya (CHIKV), Yellow fever (YFV) and Japanese encephalitis (JEV) virus in different

65 is (JEV), West Nile (WNV), and yellow fever (YFV) viruses by intracellular cytokine staining (ICS) us

66 Zika (ZIKV), West Nile (WNV), yellow fever (YFV), and tick-borne encephalitis virus (TBEV).

67 the Americas were able to transmit the five YFV genotypes, with YFV strains for Uganda and Bolivia h

68 g (VSR) encoded by the prototype flavivirus, YFV.

69 e findings have significant implications for YFV biology, vaccinology and structure-based flavivirus

70 ous sensitivities of at least 3.5 PFU/ml for YFV, 2.0 PFU/ml for JEV, 10.0 PFU/ml for WNV, and 10.0 P

71 l as the coronavirus SARS-CoV-2, but not for YFV, EBOV, VSV or HSV.

72 not previously recognized as permissive for YFV replication, and we highlight potential virus-host i

73 f the 50 samples were confirmed positive for YFV by reverse transcriptase-quantitative polymerase cha

74 Three mosquito pools were positive for YFV, 2 Haemagogus leucocelaenus, and 1 Aedes scapularis.

75 ly member, as a candidate entry receptor for YFV.

76 d LRP1 and VLDLR as additional receptors for YFV infection in cell culture.

77 te decades of study, the entry receptors for YFV remain unclear.

78 qMan fluorogenic probes (probes specific for YFV, JEV, WNV, and SLEV) and four previously published p

79 a total of 5,518 mosquitoes were tested for YFV by quantitative RT-PCR, immunohistochemistry (IHC) a

80 4-Fc and VLDLR-Fc decoys protected mice from YFV challenge, and LRP1-Fc decoys inhibited YFV infectio

81 stinal damage was a surprising feature of HA-YFV pathology.

82 Our study provides an understanding of how YFV initiates transmission in new Brazilian regions and

83 ine provides lifelong immunity against human YFV infection.

84 in one subclade of South American genotype I YFV.

85 Furthermore, TRIM56 was revealed to impair YFV and DENV2 propagation by suppressing intracellular v

86 Genetic ablation of LRP4 impaired YFV infection of cells and, reciprocally, complementatio

87 y quantifying deuterium dilution kinetics in YFV-specific CD8 T cells using mass spectrometry.

88 h a role for multiple LDLR family members in YFV entry, infection and pathogenesis, which has implica

89 Moreover, in YFV-infected hamsters, oral administration of BDAA prote

90 elates with a lack of IFN-alpha/beta-induced YFV NS5 ubiquitination in murine cells.

91 otably, DNAJC14 mutants that did not inhibit YFV replication had minimal effects on polyprotein proce

92 YFV challenge, and LRP1-Fc decoys inhibited YFV infection and liver pathogenesis in mice engrafted w

93 diazepine compound that selectively inhibits YFV by targeting the viral NS4B protein.

94 of viruses; while TRIM56 curbs intracellular YFV/DENV2 RNA replication, it acts at a later step in HC

95 olved in attenuation, a series of intratypic YFV/JEV chimeras containing either single or multiple am

96 ChimeriVax-JE) is less neurovirulent than is YFV 17D vaccine in mouse and nonhuman primate models.

97 rans-packaging system as well as full-length YFV cDNA, we report that mutation of a conserved tryptop

98 Although these long-lived YFV-specific memory CD8 T cells did not express effector

99 ives and fill a much-needed void in managing YFV cases during outbreaks.

100 Mature YFV protein associated with beta(2)m arrives on the surf

101 It has been estimated that up to 1.7 million YFV infections occur in Africa each year, resulting in 2

102 In tissue culture, this modified YFV can be further passaged at an escalating scale by us

103 We monitored YFV NS2A-5 polyprotein processing by the viral NS2B-3 pr

104 r results raise the importance of monitoring YFV viremia and suggest a potential benefit of antiviral

105 with early IFN-associated responses in naive YFV-vaccine recipients but not in primed VZV-vaccine rec

106 Soluble LRP4-Fc decoy receptors neutralized YFV infection in cell culture and reduced viral burden i

107 does not descend directly from the Nigerian YFV outbreaks of the last century, but instead reflects

108 YFV/dengue-4 virus, but not YFV/dengue-2 virus, was neurovirulent for 3-week-old mic

109 We report that like ZIKV NS5 and DENV NS5, YFV NS5 binds human STAT2 (hSTAT2) but not mouse STAT2 (

110 een demonstrated with ZIKV NS5 and DENV NS5, YFV NS5 is unable to interact with hSTAT2 in murine cell

111 a unique mechanism that involves binding of YFV NS5 to the IFN-activated transcription factor STAT2

112 Construction of YFV harboring all of the identified coding nucleotide su

113 The detection of YFV RNA in urine is an indicative of YFV infection; howe

114 f the E protein is a critical determinant of YFV neuroinvasiveness in the SCID mouse model.

115 enetic diversity and spatial distribution of YFV during the current outbreak by analyzing genomic dat

116 reflects a broader diversity and dynamics of YFV in West Africa.

117 city, functional attributes, and dynamics of YFV-specific T cell responses in vaccinated subjects by

118 n which the structural proteins prM and E of YFV 17D are replaced with those of the JEV SA14-14-2 vac

119 Here, we studied the effect of YFV, DENV, and ZKV on TCR signaling.

120 The finding of YFV by RT-PCR in five Callithrix monkeys who were all YF

121 Models were first fit to the frequency of YFV-specific memory CD8 T cells and deuterium enrichment

122 alysis of five nearly full length genomes of YFV from collected samples was consistent with evidence

123 ic data suggest there are seven genotypes of YFV that are geographically separated, and outbreaks of

124 nstructed the recent transmission history of YFV within different epidemic seasons in Brazil.

125 Our results demonstrate the importance of YFV NS5 in overcoming the antiviral action of IFN-I and

126 tion of YFV RNA in urine is an indicative of YFV infection; however, the results of RT-PCR using urin

127 n provide new insights into the landscape of YFV transmission, augmenting traditional approaches to i

128 A different dataset, on the loss of YFV-specific CD8 T cells over three decades, was used to

129 y blocking demonstrated that the majority of YFV-specific T cells were HLA-DR restricted.

130 lysine at position 326 may be a modulator of YFV virulence phenotypes.

131 plication- or packaging-deficient mutants of YFV-17D can be reconstituted in the brain, leading to ef

132 A substantial number of YFV-reactive T cells expressed memory phenotype markers

133 e result does not exclude the possibility of YFV infection.

134 Genotyping indicated the presence of YFV South American I genotype in these samples.

135 r flaviviruses, with no cross-recognition of YFV-derived peptides.

136 tion at a lysine in the N-terminal region of YFV NS5.

137 Moreover, inducible transient replication of YFV-17D mutant is sufficient to induce permanent transne

138 ligase activity, whereas its restriction of YFV and DENV2 requires both the E3 ligase activity and i

139 Overall, we found low risk of YFV introduction into the United States during the 2016-

140 vel to regions where there is a high risk of YFV transmission.

141 To gain insights into the routes of YFV introduction and dispersion, we tracked the virus by

142 Given the potential severity of YFV-induced disease, our results show that these antibod

143 ntiviral proteins were detected as a sign of YFV 17D replication.

144 ing could identify the corridor of spread of YFV.

145 rved between vaccine and virulent strains of YFV, and these are found to have significant implication

146 earched for over a century, the structure of YFV has remained elusive.

147 first high resolution cryo-EM structures of YFV.

148 son of our results and 4 previous studies of YFV nonendemic vaccinees found that overall, 79% (95% CI

149 Interestingly, while treatment of YFV infected cultures with 2 muM of BDAA reduced the vir

150 e IFN-alpha/beta-dependent ubiquitination of YFV NS5 that is required for STAT2 binding in human cell

151 ects of mutations in YFC on the viability of YFV infection were also analyzed, and these results were

152 The neuroinvasiveness of YFVs in the SCID model correlated inversely with sensiti

153 NS4A products and examined their effects on YFV replication.

154 ted in human T cells in vitro; however, only YFV inhibited TCR signaling.

155 The other, YFV, is widely transcribed and polymorphic.

156 Control mice immunized with the parental YFV-17D were not protected against DEN-2 virus challenge

157 se that interacts with and polyubiquitinates YFV NS5 to promote its binding to STAT2 and trigger IFN-

158 tly neutralizing multiple pathogenic primary YFV isolates.

159 ed whether other LDLR family members promote YFV entry.

160 LRP4 promoted YFV entry into cells through LDLR type A (LA) domain bin

161 hepatocyte cultures also resulted in reduced YFV infection.

162 ell line containing persistently replicating YFV replicon RNA).

163 As we observed residual YFV infection in LRP4-deficient cells, we evaluated whet

164 Furthermore, HLA-A2- and HLA-B7-restricted YFV epitope-specific effector cells predominantly displa

165 We demonstrate that mSTAT2 restricts YFV replication in mice and that this correlates with a

166 dition, we demonstrate that mSTAT2 restricts YFV replication in vivo These data serve as further impe

167 spersion, we tracked the virus by sequencing YFV genomes sampled from nonhuman primates and infected

168 leave specific populations at risk of severe YFV disease, as evidenced by recent outbreaks in South A

169 tablish a treatment for patients with severe YFV infection, we tested 37 YFV-specific monoclonal anti

170 ies demonstrated that expression of a short, YFV env RNA motif (vsRNA) was required and sufficient to

171 We used the live attenuated vaccine strain YFV-17D, which contains many mutations compared with vir

172 V4) and the yellow fever 17D vaccine strain (YFV-17D) did not antagonize STAT5 phosphorylation.

173 In summary, YFV in the Sao Paulo urban area was detected mainly in r

174 uctural basis for NS4B protein in supporting YFV replication.

175 NV and ZIKV immunity consistently suppressed YFV viremia.

176 d Asia, human flavivirus immunity suppresses YFV human amplification potential, reducing the risk of

177 kely due to chaperone dysregulation and that YFV probably utilizes DNAJC14's cochaperone function to

178 These data indicate that YFV/dengue virus chimeras elicit antibodies which repres

179 Longitudinal analysis indicated that YFV-specific CD4(+) T cells reached peak frequencies, of

180 Previously, we reported that YFV NS5 requires the presence of type I IFN (IFN-alpha/b

181 Ex vivo tetramer analysis revealed that YFV-specific T cells persisted at frequencies ranging fr

182 with poliovirus, these results suggest that YFV-17D encounters no major barriers during disseminatio

183 The YFV 17D-204 vaccine genome was compared to that of the p

184 ween the E proteins of ChimeriVax-JE and the YFV/JEV Nakayama virus, four of which are predicted to b

185 effect was mediated at least in part by the YFV envelope (env) protein coding RNA.

186 fore, it is unlikely that Ag is bound in the YFV ABR in the manner typical of class Ia molecules.

187 Substitutions in the YFV Ag-binding region (ABR) occur at four of the eight h

188 Related viruses in the YFV antigenic complex also showed LRP4-dependent infecti

189 g sequence and the cyclization signal in the YFV genome provides a new means for studying the mechani

190 ) or dengue-4 virus within the genome of the YFV 17D strain (YF5.2iv infectious clone) were construct

191 e A (LA) domain binding to domain III of the YFV envelope protein.

192 stal structure of the helicase region of the YFV NS3 protein includes residues 187 to 623.

193 The functional profile of the YFV-specific CD8 T cell response changed in composition

194 to restore the neurovirulence typical of the YFV/JEV Nakayama virus.

195 re analyzed for their ability to package the YFV replicon.

196 placing mSTAT2 with hSTAT2 cannot rescue the YFV NS5-STAT2 interaction, as YFV NS5 is also unable to

197 pseudo-infectious particles by supplying the YFV structural proteins using a Sindbis virus helper con

198 We show that the YFV capsid (YFC) protein inhibits RNA silencing in the m

199 rlier Nigerian isolates, suggesting that the YFV clade responsible for this outbreak in Edo State doe

200 T cell clones that expand in response to the YFV 2 weeks postvaccination (as defined by their unique

201 irmed that plasmablasts were specific to the YFV-E protein.

202 cell immunity following vaccination with the YFV 17D vaccine.

203 onstruct, the functional elements within the YFV capsid protein (YFC) were characterized.

204 Therefore, YFV elicits robust early effector CD4(+) T cell response

205 od phylogenetic analysis revealed that these YFV sequences formed a tightly clustered clade more clos

206 y or immunohistochemistry suggests that this YFV lineage circulating in Sao Paulo is associated with

207 BR specialization indicates that even though YFV is polymorphic and widely transcribed, it is, in fac

208 more than half the cases of life-threatening YFV vaccine-associated disease studied here.

209 3 to 80 yr with unexplained life-threatening YFV vaccine-associated disease.

210 for a reevaluation of current approaches to YFV immunological surveillance in South America and sugg

211 plasmic dsRNA-sensing pathways contribute to YFV induction of apoptosis, whereas only retinoic acid-i

212 xpanded clones in the absence of exposure to YFV.

213 l for the development of humoral immunity to YFV 17D vaccination in 24 study subjects.

214 viral host factor that confers resistance to YFV, DENV2, and HCoV-OC43 through overlapping and distin

215 FOXP3(+) T regulatory cells, in response to YFV vaccination preceded the kinetics of the CD8 T cell

216 cter of the primary human T cell response to YFV.

217 tiation state of the CD8+ T cell response to YFV.

218 tics, and specificity of B cell responses to YFV 17D are relatively less understood than T cell respo

219 irus structures and the phenotype similar to YFV-17D suggest that there could be future potential as

220 To better understand YFV genetic diversity and dynamics during the recent out

221 At 7 d following vaccination, YFV RNA in serum as well as several antiviral proteins w

222 tion schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (

223 The yellow fever vaccine (YFV) has been broadly used as a model to understand how

224 th the live attenuated yellow fever vaccine (YFV-17D) by sampling peripheral blood at days 0, 1, 2, 3

225 notypic differences between 17D and virulent YFV.

226 er with modeling of domain III from virulent YFV strains, the data suggest that heparin binding activ

227 mutations into infectious clones of virulent YFV genomes results in viral attenuation in vitro and in

228 corresponding gene sequences of the virulent YFV Asibi strain.

229 e to the reduced sensitivity of the virulent YFV virions to vaccine-induced antibodies.

230 ntains many mutations compared with virulent YFV.

231 fectivity phenotype, the yellow fever virus (YFV) 17D backbone of the ChimeriVax-dengue 4 virus was r

232 A neuroadapted strain of yellow fever virus (YFV) 17D derived from a multiply mouse brain-passaged vi

233 The live attenuated yellow fever virus (YFV) 17D vaccine provides a good model to study immune r

234 mpetent, live-attenuated yellow fever virus (YFV) 17D vaccine provides lifelong immunity against huma

235 s of the NS5 proteins of yellow fever virus (YFV) and dengue virus (DENV), two flaviviruses transmitt

236 Previous studies of yellow fever virus (YFV) and dengue virus have found that modifications to t

237 important flaviviruses, yellow fever virus (YFV) and dengue virus serotype 2 (DENV2), and a human co

238 S4A and NS4B proteins of Yellow Fever virus (YFV) and West Nile virus (WNV), which share similar comp

239 Arboviruses such as yellow fever virus (YFV) are transmitted between arthropod vectors and verte

240 uencing which implicated yellow fever virus (YFV) as the etiology of this outbreak.

241 tudy we characterize the Yellow Fever Virus (YFV) associated with this outbreak in Sao Paulo State, B

242 Yellow fever virus (YFV) can induce acute, life-threatening disease that is

243 The recent yellow fever virus (YFV) epidemic in Brazil in 2017 and Zika virus (ZIKV) ep

244 for vaccination against yellow fever virus (YFV) has been controversial, leading to increased scruti

245 he recent reemergence of yellow fever virus (YFV) in Brazil has raised serious concerns due to the ra

246 rated to be required for yellow fever virus (YFV) infection and others subsequently showed were also

247 es are a major target of yellow fever virus (YFV) infection, and the coagulopathy in severe YF has lo

248 rbidity and mortality of yellow fever virus (YFV) infections in Brazil, our understanding of disease

249 Here we show that yellow fever virus (YFV) inhibits IFN-I signaling through a unique mechanism

250 Yellow fever virus (YFV) is the prototype member of the genus Flavivirus, a

251 ted using as a model the yellow fever virus (YFV) live vaccine strain 17D-204 and its wild-type paren

252 ported that mutations in yellow fever virus (YFV) nonstructural protein NS2A blocked production of in

253 st Nile virus (WNV), and yellow fever virus (YFV) NS1 attenuate classical and lectin pathway activati

254 is targeted to sites of yellow fever virus (YFV) replication complex (RC) formation, where it intera

255 e a two-component genome yellow fever virus (YFV) replication system in which each of the genomes enc

256 hat involved packaging a yellow fever virus (YFV) replicon into pseudo-infectious particles by supply

257 ed prolonged presence of yellow fever virus (YFV) RNA in saliva and urine as an alternative to serum.

258 A molecular clone of yellow fever virus (YFV) strain 17D was used to identify critical determinan

259 icity of live attenuated yellow fever virus (YFV) vaccination of nonatopic subjects and patients with

260 used the live attenuated yellow fever virus (YFV) vaccine 17D as a human in vivo model to study the t

261 his issue using the live yellow fever virus (YFV) vaccine, which induces long-term immunity in humans

262 Yellow fever virus (YFV), a member of the Flavivirus genus, has a plus-sense

263 cephalitis virus (TBEV), yellow fever virus (YFV), and Japanese encephalitis virus (JEV) and by compa

264 g dengue viruses (DENV), yellow fever virus (YFV), and Zika virus (ZIKV).

265 uman pathogens including yellow fever virus (YFV), dengue virus (DENV), and Zika virus (ZKV), all of

266 barrier to infections by yellow fever virus (YFV), dengue virus serotype 2 (DENV2), and human coronav

267 severe disease caused by Yellow Fever Virus (YFV), endemic in some parts of Africa and America.

268 pecific amplification of yellow fever virus (YFV), Japanese encephalitis virus (JEV), West Nile virus

269 dengue virus (DENV) and yellow fever virus (YFV), originated in sylvatic transmission cycles involvi

270 Infection by yellow fever virus (YFV), the prototype Orthoflavivirus, induces a febrile s

271 Using yellow fever virus (YFV), we demonstrate that DNAJC14 redistributes and clus

272 or a single epitope from Yellow Fever Virus (YFV), we show that the recently described 'naive-like' m

273 NCE Flaviviruses such as yellow fever virus (YFV), Zika virus (ZIKV), and dengue virus (DENV) are imp

274 flaviviruses, including yellow fever virus (YFV), Zika virus (ZIKV), and West Nile virus (WNV), prof

275 which potently inhibits yellow fever virus (YFV).

276 dengue virus (DENV), and yellow fever virus (YFV).

277 nst the etiologic agent, yellow fever virus (YFV).

278 dengue virus (DENV) and yellow fever virus (YFV).

279 Two yellow fever virus (YFV)/dengue virus chimeras which encode the prM and E pr

280 A yellow fever virus (YFV)/Japanese encephalitis virus (JEV) chimera in which

281 a prototypic flavivirus, yellow fever virus (YFV-17D), differentially interacts with murine and human

282 fter vaccination against yellow fever virus (YFV-17D).

283 us, West Nile virus, and yellow fever virus (YFV; vaccine strain 17D) were expressed in CD4(+) T cell

284 is analysis quantifies the risk of YF virus (YFV) infected travelers arriving in the United States vi

285 Despite YF virus (YFV) transmission in major urban centers with insufficie

286 from DEN type 2 (DEN-2) virus in a YF virus (YFV-17D) genetic background.

287 live yellow-fever or varicella-zoster virus (YFV/VZV) vaccines was more suspended, with early IFN-ass

288 at all timepoints, and 24 of 38 (63.8%) were YFV seropositive at >=10 years after single-dose vaccina

289 A total of 67 monkeys were YFV-positive and 3 pools yielded YFV following culture i

290 From 542 NHP, a total of 162 NHP were YFV positive by RT-qPCR and/or immunohistochemistry, bei

291 ion (up to 69 days post-symptom onset), were YFV PCR-positive.

292 Seventy-one of 92 (77.2%) subjects were YFV seropositive (90 percent plaque reduction neutraliza

293 developed a consumptive coagulopathy whereas YFV-infected hFRG mice did not.

294 genicity of Vi-TCV when co-administered with YFV at 9 months of age and with MCV-A at 15 months of ag

295 that DNAJC14 redistributes and clusters with YFV nonstructural proteins via a transmembrane domain an

296 ble to transmit the five YFV genotypes, with YFV strains for Uganda and Bolivia having higher transmi

297 t risk of receiving a traveler infected with YFV.

298 ction of CD4(+) T cells and macrophages with YFV (17D vaccine strain) also inhibited HIV replication

299 h7 cells only marginally affected ZIKV, WNV, YFV, and TBEV replication, while DENV titers were strong

300 onkeys were YFV-positive and 3 pools yielded YFV following culture in a C6/36 cell line.